SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION Washington, D.C. 20549

OMB APPROVAL

3235-OMB Number: 0104

0.5

Estimated average burden

hours per response:

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and <i>J</i> FMR LL	orting Person [*]	2. Date of Requiring (Month/Da 09/12/20	Statement ay/Year)	3. Issuer Name and Ticker or Trading Symbol Bicara Therapeutics Inc. [BCAX]						
(Last)	st) (First) (Middle) 5 SUMMER STREET				4. Relationship of Reporting Person(s) to Issuer (Check all applicable)			5. If Amendment, Date of Original Filed (Month/Day/Year)		
(Street) BOSTON MA 02210 (City) (State) (Zip)		_		Director I 10% O Officer (give title below) I below) See Remark 1			 Individual or Joint/Group Filing heck Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person 			
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr 4)	3. Owne Form: D (D) or Ir (I) (Instr	Direct Ownership (Inst ndirect			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
(M			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversio or Exercis Price of	Form:	6. Nature of Indirect Beneficial Ownership (Instr.	
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Direct (D) or Indirect (I) (Instr. 5)	5)	
Series Seed Preferred Stock		(1)	(1)	Common Stock	10,818	(1)	Ι	F-Prime Capital Partners Life Sciences Fund VII LP		
Series B Preferred Stock		(1)	(1)	Common Stock	712,430	(1)	Ι	F-Prime Capital Partners Life Sciences Fund VII LP		
Series C Preferred Stock		(1)	(1)	Common Stock	392,085	(1)	Ι	F-Prime Capital Partners Life Sciences Fund VII LP		

Explanation of Responses:

1. The Series Seed, B, and C Preferred Shares are convertible on a 1-for-1 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration, and have no expiration date.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VII LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. (FPCPLSA) is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.

> Stephanie J. Brown, Duly 09/12/2024 authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect

subsidiaries, and Abigail P.

<u>Johnson</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.